Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection

American Journal of Gastroenterology

Volumn 105, Issue 6, 2010, Pages 1346-1353

  Nunes, David ^a   Fleming, Catherine ^a   Offner, Gwynneth ^b   Craven, Donald ^c   Fix, Oren ^a   Heeren, Timothy ^b   Koziel, Margaret J ^d,e   Graham, Camilla ^d,e   Tumilty, Sheila ^a   Skolnik, Paul ^a   Stuver, Sherri ^b   Robert Horsburgh Jr , C ^a,b   Cotton, Deborah ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; FIB 4; GLYCOPROTEIN; HYALURONIC ACID; UNCLASSIFIED DRUG; YKL 40;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIXED INFECTION; MORTALITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SURVIVAL;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 77953232889     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.746     Document Type: Article

References (33)

1. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both signifi cant fi brosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526
2. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fi brosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075
3. Forns X, Ampurdanes S, Llovet JM et al. Identifi cation of chronic hepatitis C patients without hepatic fi brosis by a simple predictive model. Hepatology 2002; 36: 986-992
4. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict signifi cant fi brosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325
5. Pares A, Deulofeu R, Gimenez A et al. Serum hyaluronate refl ects hepatic fi brogenesis in alcoholic liver disease and is useful as a marker of fi brosis. Hepatology 1996; 24: 1399-1403
6. Fontana RJ, Goodman ZD, Dienstag JL et al. Relationship of serum fi brosis markers with liver fi brosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47: 789-798
7. Larrousse M, Laguno M, Segarra M et al. Noninvasive diagnosis of hepatic fi brosis in HIV/HCV-coinfected patients. J Acquir Immune Defi c Syndr 2007; 46: 304-311
8. Cales P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fi brosis. Hepatology 2005; 42: 1373-1381
9. Rosenberg WM, Voelker M, Th iel R et al. Serum markers detect the presence of liver fi brosis: a cohort study. Gastroenterology 2004; 127: 1704-1713
10. Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fi brosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-1873
11. Manning DS, Afdhal NH. Diagnosis and quantitation of fi brosis. Gastroenterology 2008; 134: 1670-1681
12. Guechot J, Serfaty L, Bonnand AM et al. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol 2000; 32: 447-452
13. Ngo Y, Munteanu M, Messous D et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-1896.
14. Nyberg A, Lindqvist U, Engstrom-Laurent A. Serum hyaluronan and aminoterminal propeptide of type III procollagen in primary biliary cirrhosis: relation to clinical symptoms, liver histopathology and outcome. J Intern Med 1992; 231: 485-491
15. Korner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol 1996; 25: 684-688 (Pubitemid 26373886)
16. Remmel T, Remmel H, Salupere V. Aminoterminal propeptide of type III procollagen and hyaluronan in patients with primary biliary cirrhosis: markers of fi brosis in primary biliary cirrhosis. J Gastroenterol Hepatol 1996; 11: 1016-1020
17. Korner T, Kropf J, Kosche B et al. Improvement of prognostic power of the Child-Pugh classifi cation of liver cirrhosis by hyaluronan. J Hepatol 2003; 39: 947-953
18. Nojgaard C, Johansen JS, Christensen E et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003; 39: 179-186
19. Lefk owitch JH. Liver biopsy assessment in chronic hepatitis. Arch Med Res 2007; 38: 634-643
20. Regev A, Berho M, Jeff ers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618
21. Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-1355
22. Naveau S, Gaude G, Asnacios A et al. Diagnostic and prognostic values of noninvasive biomarkers of fi brosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105.
23. Skipsey K, Burleson JA, Kranzler HR. Utility of the AUDIT for identifi cation of hazardous or harmful drinking in drug-dependent patients. Drug Alcohol Depend 1997; 45: 157-163
24. Giannini E, Risso D, Botta F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-224
25. Nunes D, Fleming C, Off ner G et al. HIV infection does not aff ect the performance of noninvasive markers of fi brosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defi c Syndr 2005; 40: 538-544
26. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845
27. Yu ML, Lin SM, Lee CM et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C aft er interferon-based therapy. Hepatology 2006; 44: 1086-1097
28. Al-Mohri H, Murphy T, Lu Y et al. Evaluating liver fi brosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defi c Syndr 2007; 44: 463-469
29. Montgomery A, Ferral H, Vasan R et al. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol 2005; 28: 307-312
30. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008; 28: 110-122
31. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients wiThend-stage liver disease. Hepatology 2001; 33: 464-470
32. Kamal SM, Turner B, He Q et al. Progression of fi brosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fi brosis. Hepatology 2006; 43: 771-779
33. Pungpapong S, Nunes DP, Krishna M et al. Serum fi brosis markers accurately predict rapid fi brosis progression aft er liver transplantation for Hepatitis C. Liver Transplant 2008; 14: 1294-1302